Stockscreener 앱 받기
9.81
4.29%
-0.44
시간 외 거래:
9.93
0.12
+1.22%
전일 마감가:
$10.25
열려 있는:
$10.86
하루 거래량:
25,131
Relative Volume:
0.23
시가총액:
$165.20M
수익:
$3.25M
순이익/손실:
$-116.80M
주가수익비율:
-3.2164
EPS:
-3.05
순현금흐름:
$-98.17M
1주 성능:
-6.48%
1개월 성능:
+22.17%
6개월 성능:
+5.71%
1년 성능:
-48.04%
1일 변동 폭
$9.6633
$10.86
1주일 범위
$9.5456
$10.89
52주 변동 폭
$5.6652
$26.56
Rapt Therapeutics Inc Stock (RAPT) Company Profile
명칭
Rapt Therapeutics Inc
전화
(650) 489-9000
주소
561 ECCLES AVENUE, SOUTH SAN FRANCISCO, CA
RAPT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RAPT
Rapt Therapeutics Inc
|
9.81 | 165.20M | 3.25M | -116.80M | -98.17M | -3.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Rapt Therapeutics Inc Stock (RAPT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-30 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2025-05-22 | 재개 | H.C. Wainwright | Buy |
| 2024-12-26 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2024-11-13 | 다운그레이드 | Stifel | Buy → Hold |
| 2024-11-11 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2024-11-11 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-05-14 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2024-05-10 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2024-05-10 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-02-22 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-02-21 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-02-21 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-02-21 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-02-20 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2024-02-16 | 개시 | Evercore ISI | Outperform |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2023-09-14 | 개시 | Berenberg | Buy |
| 2023-08-09 | 개시 | Stifel | Buy |
| 2023-06-15 | 개시 | Barclays | Overweight |
| 2023-01-04 | 개시 | Guggenheim | Buy |
| 2022-12-01 | 개시 | Goldman | Buy |
| 2022-09-21 | 개시 | CapitalOne | Overweight |
| 2022-05-24 | 재개 | Cantor Fitzgerald | Overweight |
| 2021-12-09 | 개시 | JP Morgan | Overweight |
| 2021-08-12 | 개시 | SVB Leerink | Outperform |
| 2021-06-21 | 개시 | Piper Sandler | Overweight |
| 2020-06-01 | 개시 | H.C. Wainwright | Buy |
| 2020-05-19 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-04-13 | 개시 | ROTH Capital | Buy |
| 2019-11-25 | 개시 | BMO Capital Markets | Outperform |
| 2019-11-25 | 개시 | UBS | Buy |
| 2019-11-25 | 개시 | Wells Fargo | Outperform |
모두보기
Rapt Therapeutics Inc 주식(RAPT)의 최신 뉴스
Has RAPT Therapeutics Inc. formed a bullish divergenceShort-Term Market Movement Forecast Report - Newser
Sentiment analysis tools applied to RAPT Therapeutics Inc.Predictive System for Long-Term Stock Forecast - Newser
How to forecast RAPT Therapeutics Inc. trends using time seriesProfit Target Planning with Exit Confidence - Newser
Multi asset correlation models including RAPT Therapeutics Inc.Technical Insight Guide for Safer Trades - Newser
Applying Elliott Wave Theory to RAPT Therapeutics Inc.Buy and Hold Position Summary Review - Newser
Published on: 2025-08-09 04:24:12 - beatles.ru
Using AI based signals to follow RAPT Therapeutics Inc.Stock Entry Point Planner with Volume Spike - Newser
Using Ichimoku Cloud for RAPT Therapeutics Inc. technicalsAlpha Stock Picks with Chart Confirmation - Newser
Will RAPT Therapeutics Inc. continue its uptrendCapital Growth Summary Over Five Years - Newser
RAPT Therapeutics Inc. stock daily chart insightsTrade Setup Builder with Custom Alerts - Newser
Ranking RAPT Therapeutics Inc. among high performing stocks via toolsTrading Volume Anomaly Summary and Insight - Newser
Volume spikes in RAPT Therapeutics Inc. stock – what they meanTrade Setup Builder with Custom Alerts - Newser
Historical volatility pattern of RAPT Therapeutics Inc. visualizedScalable Strategy with Chart Confirmation - Newser
Analyzing drawdowns of RAPT Therapeutics Inc. with statistical toolsTechnical Long-Term Outlook and Recap Guide - Newser
RAPT Therapeutics Reports Q2 2025 Financial Results: Net Loss of $34.8 Million, Cash and Securities Valued at $169 Million. - AInvest
Full technical analysis of RAPT Therapeutics Inc. stockAlpha Trade Flow With Risk Calibration - Newser
Wells Fargo lowers Rapt Therapeutics stock price target to $38 on model changes - Investing.com Canada
Rapt Therapeutics’ Reverse Stock Split: Potential Pitfalls and Market Challenges - TipRanks
RAPT Therapeutics Reports Q2 2025 Financial Results - TipRanks
Why RAPT Therapeutics Inc. stock attracts strong analyst attentionFree Capital Growth With Controlled Risk Picks - Newser
RAPT Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Rapt Therapeutics reports Q2 EPS (65c), consensus (65c) - TipRanks
RAPT Therapeutics, Inc. SEC 10-Q Report - TradingView
RAPT Therapeutics Reports Second Quarter 2025 Financial Results - GlobeNewswire
RAPT Therapeutics Q2 revenue up 16% YoY to $7.5mln. - AInvest
RAPT Therapeutics Slashes Losses by $10M, Preps Major Food Allergy Trial Launch - Stock Titan
What machine learning models say about RAPT Therapeutics Inc.Real-Time Signal Tracking with Entry Level - Newser
Clear Street raises Rapt Therapeutics stock price target to $24 on RPT904 potential - Investing.com Canada
Rapt Therapeutics (RAPT) Expected to Announce Quarterly Earnings on Thursday - Defense World
Building trade automation scripts for RAPT Therapeutics Inc.Trade Alert System with Volume Analysis - Newser
Applying sector rotation models to RAPT Therapeutics Inc.High Reward Investment Strategy for Beginners - Newser
RAPT Therapeutics Inc. Pullback Analyzed — Is It Time to ExitEarly Breakout Entry Point Notifications Sent - beatles.ru
How does RAPT Therapeutics Inc. compare to its industry peersMaximize gains with timely market signals - Jammu Links News
Rapt Therapeutics Inc (RAPT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):